Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Summary
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Official title: A Randomized, Open-label, Multicenter Phase II Clinical Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2025-11-24
Completion Date
2029-10
Last Updated
2025-12-01
Healthy Volunteers
No
Conditions
Interventions
SHR-A2102
SHR-A2102.
Adebrelimab
Adebrelimab.
Paclitaxel
Paclitaxel.
Carboplatin
Carboplatin.
Alomnertinib Mesilate
Alomnertinib Mesilate.
Furmonertini Mesilate
Furmonertini Mesilate.
Osimertinib Mesylate
Osimertinib Mesylate.
Locations (1)
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China